/
6704.TWO
No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Gwo Xi Stem Cell Applied Technology Co. , Ltd
Gwo Xi Stem Cell Applied Technology Co., Ltd. is dedicated to advancing stem cell-based therapies, addressing critical unmet medical needs in patient care. Its product pipeline currently features two pioneering autologous adipose-derived stem cell treatments: GXHPC1, which is in Phase II clinical trials for liver cirrhosis, and GXNPC1, also undergoing Phase II testing, designed for the management of chronic stroke. Further expanding its therapeutic portfolio, the company is advancing GXCPC1, an allogeneic adipose-derived stem cell therapy currently in combined Phase I/II clinical trials for osteoarthritis, alongside GXIPC1, another allogeneic fat-derived stem cell treatment in early-stage Phase I trials for diabetes. Established in 2011, the company maintains its headquarters in Zhubei, Taiwan.
www.gwoxi.com- Employees
- 55
- IPO / List date
- Apr 26, 2023
- HQ
- TW
Held by traders on TradeandTell
No one on the platform currently holds 6704.TWO.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in 6704.TWO as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded 6704.TWO yet.